BDBM86046 R-citalopram
(S)-citalopram S(+)-citalopram BDBM50302225 CITALOPRAM ESCITALOPRAM OXALATE escitalopram (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile CHEMBL1508
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile CHEMBL549 Escitalopram [3H]Citalopram CITALOPRAM CITALOPRAM HYDROBROMIDE [3H]Lexapro [3H]Escitalopram BDBM25870 [3H]Cytalopram
Celexa CITALOPRAM HYDROBROMIDE LU-10-171-B BDBM50425188
CHEMBL1200322 BDBM50323776 ESCITALOPRAM OXALATE (S)-citalopram oxalate LU-26-054-0
- Topiol, S; Bang-Andersen, B; Sanchez, C; Plenge, P; Loland, CJ; Juhl, K; Larsen, K; Bregnedal, P; Bøgesø, KP X-ray structure based evaluation of analogs of citalopram: Compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT. Bioorg Med Chem Lett 27: 470-478 (2017)
- Zhang, P; Jørgensen, TN; Loland, CJ; Newman, AH A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett 23: 323-6 (2012)
- Kumar, V; Rahbek-Clemmensen, T; Billesbølle, CB; Jorgensen, TN; Gether, U; Newman, AH Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram. ACS Med Chem Lett 5: 696-9 (2014)
- Yarravarapu, N; Geffert, L; Surratt, CK; Cascio, M; Lapinsky, DJ Clickable photoaffinity ligands for the human serotonin transporter based on the selective serotonin reuptake inhibitor (S)-citalopram. Bioorg Med Chem Lett 28: 3431-3435 (2018)
- Kumar, V; Yarravarapu, N; Lapinsky, DJ; Perley, D; Felts, B; Tomlinson, MJ; Vaughan, RA; Henry, LK; Lever, JR; Newman, AH Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram. J Med Chem 58: 5609-19 (2015)
- Dallanoce, C; Canovi, M; Matera, C; Mennini, T; De Amici, M; Gobbi, M; De Micheli, C A novel spirocyclic tropanyl-¿²-isoxazoline derivative enhances citalopram and paroxetine binding to serotonin transporters as well as serotonin uptake. Bioorg Med Chem 20: 6344-55 (2012)
- Millan, MJ; Gobert, A; Lejeune, F; Newman-Tancredi, A; Rivet, JM; Auclair, A; Peglion, JL S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298: 565-80 (2001)
- Zhang, P; Cyriac, G; Kopajtic, T; Zhao, Y; Javitch, JA; Katz, JL; Newman, AH Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters. J Med Chem 53: 6112-21 (2010)
- Banala, AK; Zhang, P; Plenge, P; Cyriac, G; Kopajtic, T; Katz, JL; Loland, CJ; Newman, AH Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites. J Med Chem 56: 9709-24 (2013)
- ChEBML_202161 Displacement of [3H]-citalopram from Serotonin transporter
- ChEMBL_326608 (CHEMBL863451) Displacement of [3H]citalopram from SERT
- ChEMBL_330473 (CHEMBL869979) Displacement of [3H]citalopram from SERT
- ChEMBL_355134 (CHEMBL853187) Displacement of [3H]citalopram from SERT
- ChEMBL_439700 (CHEMBL888811) Displacement of [3H]citalopram from SERT
- ChEMBL_566867 (CHEMBL958367) Displacement of [3H]citalopram from SERT
- ChEMBL_198043 (CHEMBL800740) Inhibition of [3H]- citalopram binding to Serotonin transporter
- ChEMBL_202161 (CHEMBL808864) Displacement of [3H]-citalopram from Serotonin transporter
- ChEMBL_326653 (CHEMBL870558) Displacement of [3H]Citalopram from human SERT
- ChEMBL_409349 (CHEMBL912350) Displacement of [3H]citalopram from human SERT
- ChEMBL_486189 (CHEMBL1016597) Displacement of [3H]citalopram from serotonin transporter
- ChEMBL_539635 (CHEMBL1025640) Displacement of [3H]citalopram from human SERT
- ChEMBL_604292 (CHEMBL1066748) Displacement of [3H]Citalopram from human SERT
- ChEMBL_652475 (CHEMBL1225678) Displacement of [3H]Citalopram from human SERT
- ChEBML_201368 Binding affinity to serotonin transporter, using [3H]citalopram as radioligand
- ChEBML_305921 Inhibition of [3H]citalopram binding to human serotonin transporter (hSERT)
- ChEMBL_201223 (CHEMBL801199) Binding affinity of [3H]citalopram for serotonin transporter in monkey
- ChEMBL_428746 (CHEMBL916722) Displacement of [3H]citalopram from rat cortex SERT
- ChEMBL_454705 (CHEMBL886727) Displacement of [3H]citalopram from rat brain SERT
- ChEMBL_457103 (CHEMBL924479) Displacement of [3H]citalopram from SERT in rat brain
- ChEMBL_535431 (CHEMBL984460) Displacement of [3H]citalopram from rat brain SERT
- ChEMBL_595537 (CHEMBL1048772) Displacement of [3H]citalopram from SERT in rat brain
- ChEMBL_809994 (CHEMBL2015103) Displacement of [3H]citalopram from human serotonin transporter
- ChEBML_201657 Inhibition of binding of [3H]citalopram to (SERT) serotonin transporter in rat striatum
- ChEBML_201971 Displacement of [3H]citalopram from serotonin transporter of rat brain membrane
- ChEBML_201983 Inhibition of [3H]citalopram binding to Serotonin transporter of rat cerebral cortex
- ChEBML_201987 Ability to displace [3H]citalopram radioligand, for the Serotonin transporter in rat brain
- ChEMBL_443351 (CHEMBL893599) Displacement of [3H]citalopram from Sprague-Dawley rat SERT
- ChEMBL_522451 (CHEMBL1001584) Displacement of [3H]citalopram from 5HTT in rat brain membranes
- ChEMBL_201221 (CHEMBL801197) Binding affinity against serotonin transporter by using [3H]-citalopram as a radioligand
- ChEMBL_201642 (CHEMBL806543) Binding affinity at serotonin transporter in rat striatum by [3H]citalopram displacement.
- ChEMBL_201657 (CHEMBL803031) Inhibition of binding of [3H]citalopram to (SERT) serotonin transporter in rat striatum
- ChEMBL_201830 (CHEMBL805337) Binding affinity at serotonin transporter in rat brain by [3H]-citalopram displacement.
- ChEMBL_201971 (CHEMBL804808) Displacement of [3H]citalopram from serotonin transporter of rat brain membrane
- ChEMBL_201972 (CHEMBL804974) Displacement of [3H]-citalopram from serotonin transporter of rat brain membrane
- ChEMBL_201987 (CHEMBL809432) Ability to displace [3H]citalopram radioligand, for the Serotonin transporter in rat brain
- ChEMBL_2034398 (CHEMBL4688556) Displacement of [3H]-citalopram from human SERT by liquid scintillation counting
- ChEMBL_305949 (CHEMBL832789) Inhibition of [3H]citalopram binding to serotonin transporter of rat cerebral cortex
- ChEMBL_395401 (CHEMBL908066) Displacement of [3H]citalopram from human SERT transfected in HEK293 cells
- ChEMBL_418046 (CHEMBL911774) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat brain
- ChEMBL_432257 (CHEMBL914035) Displacement of [3H]citalopram from SERT in rhesus monkey caudate-putamen
- ChEMBL_436643 (CHEMBL904953) Displacement of [3H]citalopram from 5HTT in Sprague-Dawley rat cerebrum
- ChEMBL_443460 (CHEMBL893718) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells
- ChEMBL_444174 (CHEMBL893333) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells
- ChEMBL_460400 (CHEMBL927452) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells
- ChEMBL_466323 (CHEMBL947040) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells
- ChEMBL_473952 (CHEMBL950333) Inhibition of [3H]Citalopram uptake in human 5HTT transfected HEK293 cells
- ChEMBL_496792 (CHEMBL1008805) Displacement of [3H]citalopram from SERT in rat brain stem membrane
- ChEMBL_501245 (CHEMBL976147) Displacement of [3H]citalopram human SerT receptor expressed in LLCPK cells
- ChEMBL_509624 (CHEMBL1001385) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells
- ChEMBL_556830 (CHEMBL964690) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells
- ChEMBL_630104 (CHEMBL1110024) Displacement of [3H]citalopram form human SRET by liquid scintillation counting
- ChEMBL_646992 (CHEMBL1217133) Displacement of [3H](R,S)-citalopram HBr from human SERT
- ChEMBL_698907 (CHEMBL1645847) Displacement of [3H]citalopram from human SERT by scintillation proximity assay
- ChEMBL_700848 (CHEMBL1646407) Displacement of [3H]citalopram from human SERT expressed in HEK cells
- ChEMBL_821406 (CHEMBL2037807) Displacement of [3H]Citalopram from human SERT by liquid scintillation counting
- ChEMBL_879499 (CHEMBL2208897) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells
- ChEBML_201337 Inhibition of [3H]citalopram binding to serotonin transporter (SERT) of cynomolgus monkey caudate-putamen
- ChEBML_201821 Binding affinity at Serotonin transporter using [3H]citalopram as radioligand from rat brain
- ChEMBL_142779 (CHEMBL750499) Compound was tested for its ability to displace [3H]citalopram from norepinephrine transporter
- ChEMBL_1452256 (CHEMBL3366168) Displacement of [3H]Citalopram from human Serotonin transporter by liquid scintillation counting
- ChEMBL_198044 (CHEMBL800741) Inhibition of binding of [3H]- citalopram to Serotonin transporter (SERT) of rat cerebral cortex.
- ChEMBL_201222 (CHEMBL801198) Ability to inhibit [3H]citalopram binding to serotonin transporter in cynomolgus monkey striatum
- ChEMBL_201340 (CHEMBL806863) Inhibition of [3H]- citalopram binding to serotonin transporter of Cynomolgus monkey caudate-putamen
- ChEMBL_201506 (CHEMBL805633) In vitro binding affinity at serotonin transporter in rat striatum by [3H]- citalopram displacement.
- ChEMBL_201667 (CHEMBL803041) In vitro inhibition of [3H]citalopram binding to serotonin transporter on rat striatal membranes.
- ChEMBL_201816 (CHEMBL805324) Binding affinity against serotonin transporter by displacement of [3H]citalopram in rat brain
- ChEMBL_201832 (CHEMBL805339) Binding affinity towards serotonin transporter using [3H]citalopram as radioligand was determined
- ChEMBL_226363 (CHEMBL847531) Ability to inhibit [3H]citalopram binding to serotonin transporter in cynomolgus monkey striatum
- ChEMBL_444106 (CHEMBL892232) Displacement of [3H]citalopram from human 5HT transporter expressed in HEK293 cells
- ChEMBL_469465 (CHEMBL948024) Displacement of [3H]-citalopram from human SERT expressed in HEK293 cell membrane
- ChEMBL_490419 (CHEMBL985552) Inhibition of [3H]citalopram uptake at human 5HTT expressed in HEK293 cells by SPA
- ChEMBL_492741 (CHEMBL938541) Displacement of [3H]citalopram from human SerT expressed pig LLCPK cells
- ChEMBL_560275 (CHEMBL1020453) Displacement of [3H]citalopram from human SERT receptor expressed in HEK293 cells
- ChEMBL_607219 (CHEMBL1068051) Displacement of [3H]citalopram from human cloned SERT expressed in HEK293 cells
- ChEMBL_613776 (CHEMBL1068923) Displacement of [3H]citalopram from mouse cortex SERT by filtration binding assay
- ChEMBL_649987 (CHEMBL1219685) Displacement of [3H]citalopram from SERT in rat brain stem by scintillation counting
- ChEMBL_686391 (CHEMBL1293147) Displacement of [3H]-citalopram in human SERT expressed in LLCPK cells by filtration assay
- ChEMBL_700609 (CHEMBL1648598) Displacement of [3H]citalopram from human SERT expressed in HEK293 cell membrane
- ChEMBL_718912 (CHEMBL1681406) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat brain membranes
- ChEMBL_959040 (CHEMBL2382973) Displacement of [3H]citalopram from human SERT expressed in HEK293 cell membranes
- ChEBML_184440 Displacement of specific [3H]- citalopram binding to 5-HT uptake site in rat whole cortex
- ChEBML_201974 Compound was evaluated for its ability to displace [3H]citalopram binding to the rat cortical Serotonin transporter
- ChEMBL_201226 (CHEMBL801382) Inhibition of [3H]citalopram binding to the serotonin transporter (5-HT) in monkey caudate-putamen.
- ChEMBL_201337 (CHEMBL806861) Inhibition of [3H]citalopram binding to serotonin transporter (SERT) of cynomolgus monkey caudate-putamen
- ChEMBL_201516 (CHEMBL807133) Binding affinity towards serotonin transporter in rat striatum using [3H]citalopram as radioligand
- ChEMBL_201647 (CHEMBL806548) IC50 value was evaluated using [3H]citalopram (radioligand) on serotonin transporter in rat striatum.
- ChEMBL_201653 (CHEMBL873136) Inhibition of [3H]citalopram binding to Serotonin transporter (5-HTT) in rat cortical tissue.
- ChEMBL_201968 (CHEMBL804805) Compound is evaluated for binding to Serotonin transporter using [3H]citalopram as radioligand in rat brain
- ChEMBL_2133327 (CHEMBL4842937) Displacement of [3H]citalopram from human SERT in HEK293 cells by Topcount scintillation analysis
- ChEMBL_306337 (CHEMBL828157) Inhibitory activity against human- serotonin reuptake transmitter using [3H]-citalopram as a radioligand
- ChEMBL_600324 (CHEMBL1038400) Displacement of [3H]citalopram from SERT in rat cerebral cortex by liquid scintillation counting
- ChEMBL_664681 (CHEMBL1260567) Displacement of [3H]-citalopram from human serotonin transporter expressed in HEK 293 cells
- ChEMBL_715436 (CHEMBL1664821) Displacement of [3H]citalopram from SERT in rat cerebral cortex by liquid scintillation counting
- ChEMBL_801860 (CHEMBL1947472) Displacement of [3H]Citalopram from human cloned SERT receptor expressed in HEK293 cells
- ChEMBL_856515 (CHEMBL2161561) Displacement of [3H]-citalopram from SERT in rat cortical membranes after 60 mins
- ChEMBL_1365903 (CHEMBL3296598) Displacement of [3H]-S-citalopram from human SERT expressed in African green monkey COS7 cells incubated for 10 mins prior to [3H]-S-citalopram addition measured after 2 hrs by scintillation counting analysis
- ChEBML_201513 Binding affinity was evaluated by measuring inhibiting the binding of [3H]citalopram to Serotonin transporter in rat brain tissue
- ChEMBL_1789089 (CHEMBL4260823) Displacement of [3H]Citalopram from human SERT expressed in HEK cells by radioligand binding assay
- ChEMBL_201224 (CHEMBL801200) Inhibition of [3H]citalopram binding to the serotonin transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.
- ChEMBL_201227 (CHEMBL801383) Inhibition of [3H]citalopram binding to the serotonin transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.
- ChEMBL_201228 (CHEMBL801384) Inhibition of [3H]citalopram binding to the serotonin transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.
- ChEMBL_201344 (CHEMBL806206) Affinity was evaluated using [3H]citalopram (radioligand) on human serotonin transporter expressed in HEK cells
- ChEMBL_201483 (CHEMBL805240) Inhibition constant against [3H]citalopram in murine kidney cells transfected with human serotonin transporter.
- ChEMBL_201486 (CHEMBL805243) Inhibitory constant against human serotonin transporter using [3H]N-Me-citalopram radioligand
- ChEMBL_201487 (CHEMBL805618) Inhibitory constant against human serotonin transporter using [3H]N-Me-citalopram radioligand
- ChEMBL_201512 (CHEMBL806971) Binding affinity at serotonin transporter from rat brain striatal membrane by [3H]citalopram displacement.
- ChEMBL_201640 (CHEMBL806541) Compound was tested for inhibition of [3H]citalopram binding at the serotonin transporter in rat fore brain membranes
- ChEMBL_201825 (CHEMBL805332) Binding affinity for serotonin transporter was determined in vitro in rat brain using [3H]citalopram as radioligand.
- ChEMBL_201974 (CHEMBL804976) Compound was evaluated for its ability to displace [3H]citalopram binding to the rat cortical Serotonin transporter
- ChEMBL_202302 (CHEMBL812555) Effect of compound on Serotonin transporter uptake from rat cortex using [3H]citalopram as radioligand
- ChEMBL_2068295 (CHEMBL4723548) Displacement of [3H]citalopram from serotonin transporter (unknown origin) by liquid scintillation counting method
- ChEMBL_303776 (CHEMBL830133) In vitro inhibition of [3H]citalopram binding to human serotonin transporter expressed in human HEK293 cells
- ChEMBL_609535 (CHEMBL1073788) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells by scintillation proximity assay
- ChEMBL_61669 (CHEMBL670047) Inhibition constant against [3H]citalopram in murine kidney cells transfected with human dopamine transporter
- ChEMBL_634877 (CHEMBL1120509) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells by scintillation proximity assay
- ChEBML_201998 In vitro binding affinity towards serotonin transporter using [3H]citalopram as radioligand in rat cerebral cortex membranes
- ChEMBL_1462643 (CHEMBL3399330) Displacement of [3H]citalopram from rat brain cerebral cortex SERT by liquid scintillation counting analysis
- ChEMBL_1923206 (CHEMBL4426162) Displacement of [3H]citalopram from human SERT expressed in HEK293 cells measured after 30 mins
- ChEMBL_201513 (CHEMBL806972) Binding affinity was evaluated by measuring inhibiting the binding of [3H]citalopram to Serotonin transporter in rat brain tissue
- ChEMBL_201662 (CHEMBL803036) Inhibitory activity against serotonin transporter (SERT) labeled with [3H]-citalopram in rat brain striatal membrane.
- ChEMBL_304045 (CHEMBL840222) Binding affinity towards human serotonin transporter expressed in LLCPK cells using the radioligand [3H]citalopram
- ChEMBL_559244 (CHEMBL1014663) Displacement of [3H]citalopram from SERT in Sprague-dawley rat frontal cortex by liquid scintillation spectrophotometry
- ChEMBL_581593 (CHEMBL1062480) Displacement of [3H]citalopram from human recombinant SERT expressed in HEK293 cells by scintillation proximity assay
- ChEMBL_599587 (CHEMBL1040199) Displacement of [3H]citalopram from human serotonin transporter expressed in HEK293 cells by scintillation proximity assay
- ChEMBL_642191 (CHEMBL1176742) Displacement of [3H]-citalopram from SERT in mouse cortex after 2 hrs by liquid scintillation counting
- ChEMBL_935741 (CHEMBL2321505) Displacement of [3H]-citalopram from SERT in rat cerebral cortex after 1 hr by scintillation counting
- ChEBML_1586517 Displacement of [3H]Citalopram from human SERT expressed in cell membranes after 1 hr by liquid scintillation counting
- ChEBML_1698011 Displacement of [3H]-citalopram from SERT in Sprague-Dawley rat midbrain after 60 mins by scintillation counting method
- ChEMBL_1499800 (CHEMBL3582630) Displacement of [3H]citalopram from human recombinant SERT expressed in HEK cell membranes by radioligand binding assay
- ChEMBL_1586247 (CHEMBL3820065) Displacement of [3H]Citalopram from human recombinant SERT incubated for 1.5 hrs by microbeta scintillation counting method
- ChEMBL_201478 (CHEMBL804587) In vitro affinity determined using [3H]citalopram in murine kidney cells transfected with human serotonin transporter (SERT)
- ChEMBL_201981 (CHEMBL809426) In vitro binding affinity for serotonin transporter RB5-HT-T in rat cortical membranes by [3H]citalopram displacement.
- ChEMBL_2106951 (CHEMBL4815626) Displacement of [3H]-citalopram from human SERT receptor incubated for 1 hr by liquid scintillation counting method
- ChEMBL_664682 (CHEMBL1260568) Displacement of [3H]-citalopram from human serotonin transporter expressed in HEK 293 cells by scintillation proximity assay
- ChEBML_1677355 Displacement of [3H]citalopram from Sprague-Dawley rat brain SERT after 60 mins by liquid scintillation counting method
- ChEMBL_1278612 (CHEMBL3095443) Displacement of [3H]citalopram from Sprague-Dawley rat brain stem SERT site S1 by scintillation counting analysis
- ChEMBL_1586517 (CHEMBL3821456) Displacement of [3H]Citalopram from human SERT expressed in cell membranes after 1 hr by liquid scintillation counting
- ChEMBL_1867021 (CHEMBL4367996) Displacement of [3H]-citalopram from SERT in rat cortex tissue incubated for 60 mins by microbeta scintillation counting method
- ChEMBL_201338 (CHEMBL882391) Inhibition of [3H]citalopram binding to the serotonin transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen.
- ChEMBL_201482 (CHEMBL804591) In vitro competitive binding versus [3H]citalopram in murine kidney cells transfected with cDNA for human serotonin transporter (SERT)
- ChEMBL_201488 (CHEMBL805619) In vitro competitive binding versus [3H]-citalopram in murine kidney cells transfected with cDNA for human serotonin transporter (SERT)
- ChEMBL_2223723 (CHEMBL5137236) Displacement of [3H]-citalopram from SERT in Sprague-Dawley rat brainstem incubated for 60 mins by radioligand binding assay
- ChEMBL_2275538 Displacement of [3H]-citalopram from human 5-HT7 expressed in human HEK cells assessed as inhibition constant by FLIPR assay
- ChEMBL_598778 (CHEMBL1042018) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat brain after 2 hrs by liquid scintillation analysis
- ChEMBL_802188 (CHEMBL1949346) Displacement of [3H]-Citalopram from SERT in rat cerebral cortex homogenates after 1 hr by liquid scintillation counter
- ChEMBL_901160 (CHEMBL3062629) Displacement of [3H]Citalopram from SERT in rat cerebral cortex after 1 hr by liquid scintillation counting analysis
- ChEBML_1689230 Displacement of [3H]Citalopram from human SERT receptor expressed in HEK cell membranes after 90 mins by scintillation counting method
- ChEMBL_1295094 (CHEMBL3129469) Displacement of [3H]citalopram from Sprague-Dawley rat brain SERT after 60 mins by liquid scintillation counting analysis
- ChEMBL_1339949 (CHEMBL3243819) Displacement of [3H]-N-methyl-citalopram from SERT in human platelets after 60 mins by liquid scintillation counting analysis
- ChEMBL_1677355 (CHEMBL4027498) Displacement of [3H]citalopram from Sprague-Dawley rat brain SERT after 60 mins by liquid scintillation counting method
- ChEMBL_1755214 (CHEMBL4189974) Displacement of [3H]-Citalopram from human SERT expressed in HEK293 cell membranes after 90 mins by scintillation counting method
- ChEMBL_1768880 (CHEMBL4220992) Displacement of [3H]-citalopram from human SERT expressed in HEK293 cell membranes after 60 mins by liquid scintillation counting
- ChEMBL_1898946 (CHEMBL4401061) Displacement of [3H]-citalopram from SERT in rat cortex tissue measured after 60 mins by microbeta scintillation counting analysis
- ChEMBL_201336 (CHEMBL806185) In vitro affinity for serotonin transporter in Rhesus (Macaca mulatta) or Cynomolgus (Macaca fasicularis) monkey striata using [3H]citalopram displacement.
- ChEMBL_2169953 (CHEMBL5055012) Displacement of [3H]-citalopram from human SERT expressed in HEK cell membrane assessed as inhibition constant by radioligand binding assay
- ChEMBL_687284 (CHEMBL1291960) Displacement of [3H]citalopram from serotonin transporter in Sprague-Dawley rat brain after 1 hr by liquid scintillation counting
- ChEMBL_793035 (CHEMBL1932601) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat brain homogenates after 60 mins by liquid scintillation counting
- ChEMBL_969677 (CHEMBL2406786) Displacement of [3H]Citalopram from SERT in Sprague-Dawley rat brain homogenate after 60 mins by scintillation counting analysis
- ChEMBL_1547206 (CHEMBL3756313) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat whole brain membranes after 1 hr by liquid scintillation spectrometry
- ChEMBL_1621704 (CHEMBL3863987) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat brain stem membranes incubated for 60 mins by radioligand binding assay
- ChEMBL_1627315 (CHEMBL3869836) Displacement of [3H]Citalopram from human SERT expressed in HEK cells measured after 90 mins by microbeta scintillation counting method
- ChEMBL_1629249 (CHEMBL3871875) Displacement of [3H]citalopram from human SERT expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting method
- ChEMBL_1980752 (CHEMBL4614014) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat midbrain membranes incubated for 60 mins by microbeta scintillation counting method
- ChEMBL_2056021 (CHEMBL4711022) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat midbrain membranes incubated for 60 mins by microbeta scintillation counting method
- ChEMBL_1350019 (CHEMBL3270819) Displacement of [3H]citalopram from SERT in Sprague-Dawley rat whole brain membranes after 1 hr by liquid scintillation spectrophotometric analysis
- ChEMBL_1737693 (CHEMBL4153443) Displacement of [3H]-Citalopram from human SERT receptor expressed in stable HEK cells after 90 mins by microbeta scintillation counting method
- ChEMBL_1890404 (CHEMBL4392158) Displacement of [3H]-citalopram from human SERT receptor expressed in stable HEK cells after 90 mins by microbeta scintillation counting method
- ChEMBL_2157776 (CHEMBL5042436) Displacement of [3H]-Citalopram from NET (unknown origin) expressed in HEK cell membrane incubated for 2 hrs by liquid scintillation counter analysis
- ChEMBL_1347685 (CHEMBL3271086) Displacement of [3H]-citalopram from SERT in Sprague-Dawley rat cortex, striatum and cerebellum-dissected brain after 60 mins by scintillation counting analysis
- ChEMBL_1652598 (CHEMBL4001853) Displacement of [3H]-(+/-)-citalopram from Sprague-Dawley rat brain SERT primary site (S1) after 2 hrs by liquid scintillation counting method
- ChEMBL_1895388 (CHEMBL4397423) Displacement of [3H]-citalopram from recombinant human SERT stably expressed in HEK cells measured after 90 mins by microbeta scintillation counting method
- ChEMBL_1904420 (CHEMBL4406642) Displacement of [3H]-citalopram from human SERT receptor expressed in stable HEK cell membranes after 90 mins by microbeta scintillation counting method
- ChEMBL_2157777 (CHEMBL5042437) Displacement of [3H]-Citalopram from SERT receptor (unknown origin) expressed in HEK cell membrane incubated for 2 hrs by liquid scintillation counter analysis
- ChEMBL_2157779 (CHEMBL5042439) Displacement of [3H]-Citalopram from sigma-2 receptor (unknown origin) expressed in HEK cell membrane incubated for 2 hrs by liquid scintillation counter analysis
- ChEMBL_2157780 (CHEMBL5042440) Displacement of [3H]-Citalopram from sigma-1 receptor (unknown origin) expressed in HEK cell membrane incubated for 2 hrs by liquid scintillation counter analysis
- ChEMBL_1652599 (CHEMBL4001854) Inhibition of [3H]-S-citalopram dissociation from SERT allosteric modulator site (S2) (unknown origin) expressed in African green monkey COS1 cell membranes by scintillation counting method
- ChEMBL_1278605 (CHEMBL3095436) Allosteric modulation at wild-type human SERT site S2 expressed in african green monkey COS7 cells assessed as inhibition of [3H]citalopram dissociation at 30 uM by scintillation counting analysis
- ChEMBL_1652592 (CHEMBL4001847) Displacement of [3H]-S-citalopram from human SERT primary site (S1) expressed in African green monkey COS7 cell membranes after 2 hrs by microbeta scintillation counting method
- Serotonin, Transporter SERT (h) Assay Type: BindingSpecies: HumanOrigin: PlateletsLigand: [3H]Citalopram, N-MethylLigand [M]: 7.00E-10Kd (Binding Affinity): 2.50E-09Bmax: 425 fmol/mg proteinMethod: RadioactivityMeasurement: DPM
- ChEMBL_1652593 (CHEMBL4001848) Inhibition of [3H]-S-citalopram dissociation from human SERT allosteric modulator site (S2) expressed in African green monkey COS7 cell membranes after 90 mins by scintillation counting method
- ChEMBL_1652600 (CHEMBL4001855) Inhibition of [3H]-S-citalopram dissociation from human SERT allosteric modulator site (S2) expressed in African green monkey COS7 cell membranes after 80 mins by microbeta scintillation counting method
- h-SERT Binding Assay The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In specific, a solution of 200 μL in total was prepared by mixing 50 μL of [3H] citalopram (manufactured by GE Healthcare) diluted with a SERT buffer (final concentration: about 2 nmol/L), 149 μL of the h-SERT/CHO membrane preparation (protein amount: 40 μg/well), and 1 μL of the test drug dissolved in dimethylsulfoxide. The solution was reacted at room temperature for 60 minutes, and then quickly suction-filtered under reduced pressure through a glass fiber filter coated with 0.05% aq. polyethyleneimine. The glass fiber filter was washed twice with 250 HL of the SERT buffer, placed in a plastic vial containing 4 mL of liquid scintillator (ACS-II, manufactured by Amersham) or Ecoscint A (manufactured by National Diagnostics), and the remaining radioactivity on the filter paper was assayed with a liquid scintillation counter. The non-specific binding of [3H] citalopram was defined as a binding amount in the presence of 1 μmol/L clomipramine (manufactured by Sigma Aldrich) The IC50 value was calculated according to Hill analysis [see, Hill A. V., J. Physiol., 40, 190-200 (1910)], and the binding inhibition constant (Ki) was calculated according to the following formula: Binding inhibition constant (Ki)=IC50/(1+S/Kd) wherein S is a concentration of the added [3H] citalopram, and Kd is a binding dissociation constant of [3H] citalopram which was calculated from a saturated binding assay using the same cell membrane. A lower Ki value (i.e. a lower h-SERT binding inhibition constant) means that the test drug has a stronger human serotonin reuptake inhibitory action.
- h-SERT Binding Assay The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In specific, a solution of 200 μL in total was prepared by mixing 50 μL of [3H] citalopram (manufactured by GE Healthcare) diluted with a SERT buffer (final concentration: about 2 nmol/L), 149 μL of the h-SERT/CHO membrane preparation (protein amount: 40 μg/well), and 1 μL of the test drug dissolved in dimethylsulfoxide. The solution was reacted at room temperature for 60 minutes, and then quickly suction-filtered under reduced pressure through a glass fiber filter coated with 0.05% aq. polyethyleneimine. The glass fiber filter was washed twice with 250 HL of the SERT buffer, placed in a plastic vial containing 4 mL of liquid scintillator (ACS-II, manufactured by Amersham) or Ecoscint A (manufactured by National Diagnostics), and the remaining radioactivity on the filter paper was assayed with a liquid scintillation counter. The non-specific binding of [3H] citalopram was defined as a binding amount in the presence of 1 μmol/L clomipramine (manufactured by Sigma Aldrich) The IC50 value was calculated according to Hill analysis [see, Hill A. V., J. Physiol., 40, 190-200 (1910)], and the binding inhibition constant (Ki) was calculated according to the following formula:Binding inhibition constant (Ki)=IC50/(1+S/Kd)wherein S is a concentration of the added [3H] citalopram, and Kd is a binding dissociation constant of [3H] citalopram which was calculated from a saturated binding assay using the same cell membrane. A lower Ki value (i.e. a lower h-SERT binding inhibition constant) means that the test drug has a stronger human serotonin reuptake inhibitory action.
- Receptor Binding Assay [3H] citalopram binding was assayed according to the method of Owens et al. [Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997)]. Specifically, 50 ul of [3H] citalopram (final concentration: approximately 2 nM) diluted with SERT buffer, 149 ul of the h-SERT/CHO membrane preparation (40 ug/well in terms of the amount of the protein), and 1 ul of a solution of a test drug dissolved in DMSO were added to prepare 200 ul in total of a solution. This solution was reacted at room temperature for 60 minutes and then immediately suction-filtered at a low pressure using a glass fiber filter paper coated with a 0.05% aqueous polyethyleneimine solution. The glass fiber filter paper was washed twice with 250 ul of SERT buffer and then transferred to a glass vial containing 4 ml of ACS-II (manufactured by GE Healthcare (formerly Amersham Biosciences)). Radioactivity remaining on the filter paper was measured using a liquid scintillation counter.
- Binding Assay Serotonin Transporter Binding Assay. Brains from male Sprague-Dawley rats weighing 200-225 g (Taconic Labs, Germantown, N.Y.) were removed, midbrain dissected and rapidly frozen. Membranes were prepared by homogenizing tissues in 20 volumes (w/v) of 50 mM Tris containing 120 mM NaCl and 5 mM KCl, (pH 7.4 at 25° C.), using a Brinkman Polytron and centrifuged at 50,000×g for 10 min at 4° C. The resulting pellet was resuspended in buffer, recentrifuged and resuspended in buffer to a concentration of 15 mg/mL. Ligand binding experiments were conducted in assay tubes containing 0.5 mL buffer for 60 min at room temperature. Each tube contained 1.4 nM [3H]Citalopram (Amersham Biosciences, Piscataway, N.J.) and 1.5 mg midbrain tissue (original wet weight). Nonspecific binding was determined using 10 mM fluoxetine. Incubations were terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.3% polyethylenimine, using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, Md.). The filters were washed twice with 3 mL cold buffer and transferred to scintillation vials. Beckman Ready Value (3.0 mL) was added and the vials were counted the next day using a Beckman 6000 liquid scintillation counter (Beckman Coulter Instruments, Fullerton, Calif.). Each compound was tested with concentrations ranging from 0.01 nM to 100 mM for competition against binding of [3H]Citalopram, in at least three independent experiments, each performed in triplicate. Data were analyzed with GraphPad Prism software (San Diego, Calif.).
- Serotonin Transporter Binding Assay Serotonin Transporter Binding Assay. Brains from male Sprague-Dawley rats weighing 200-225 g (Taconic Labs, Germantown, N.Y.) were removed, midbrain dissected and rapidly frozen. Membranes were prepared by homogenizing tissues in 20 volumes (w/v) of 50 mM Tris containing 120 mM NaCl and 5 mM KCl, (pH 7.4 at 25° C.), using a Brinkman Polytron and centrifuged at 50,000×g for 10 min at 4° C. The resulting pellet was resuspended in buffer, recentrifuged and resuspended in buffer to a concentration of 15 mg/mL. Ligand binding experiments were conducted in assay tubes containing 0.5 mL buffer for 60 min at room temperature. Each tube contained 1.4 nM [3H]Citalopram (Amersham Biosciences, Piscataway, N.J.) and 1.5 mg midbrain tissue (original wet weight). Nonspecific binding was determined using 10 mM fluoxetine. Incubations were terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.3% polyethylenimine, using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, Md.). The filters were washed twice with 3 mL cold buffer and transferred to scintillation vials. Beckman Ready Value (3.0 mL) was added and the vials were counted the next day using a Beckman 6000 liquid scintillation counter (Beckman Coulter Instruments, Fullerton, Calif.). Each compound was tested with concentrations ranging from 0.01 nM to 100 mM for competition against binding of [3H]Citalopram, in at least three independent experiments, each performed in triplicate. Data were analyzed with GraphPad Prism software (San Diego, Calif.).
- In vitro Binding Affinity Assay The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30 volumes of ice-cold 50mM Tris-HCl containing 150mM NaCl and 5mM KCl, pH 7.7, at 25°C and centrifuged at 20,000 x g for 20 min. Pellet was resuspended in 30 volumes of buffer and centrifuged again for 2 more times. The mixture of 240uL of the tissue suspension, 30uL of 1µM imipramine, 30uL of 1nM [3H]-citalopram and 100µL of the analyzed compound (10^-10 to 10^-4M) were incubated at 22°C for 1 h. Incubations were terminated by vacuum filtration and washed twice with 100µL of ice-cold buffer. The radioactivity was measured using a WALLAC 1409 DSA liquid scintillation counter.
- Competition Binding Assay The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine or [3H]citalopram binding assays in recombinant human DAT, NET and SERT membranes with the SPA technology. The final assay volume is 50 μL in 384 well plates.Briefly, 0.5 μL of test compound in neat DMSO or 0.5 μL of DMSO for total binding (TB) or 0.5 μL of indatraline 1 mM (10 μM final concentration) for non specific binding (NSB) are added to the assay plate. 50 μL of the SPA mixture is added to each well, containing: 30 μg/mL or 10 μg/mL or 25 μg/mL DAT, NET, SERT membranes, respectively; 5 nM [3H]WIN-35,428 or 5 nM [3H]nisoxetine or 1 nM [3H]citalopram, for DAT, NET, SERT assay, respectively; 2.5 mg/mL or 1 mg/mL or 4 mg/mL WGA-PVT SPA beads (PerkinElmer RPNQ0001, for DAT, NET, SERT assay, respectively. All components are added to Assay Buffer (20 mM HEPES pH 7.4, 145 mM NaCl, 5 mM KCl, 0.01% Pluronic F-127). 0.02% BSA was used for DAT binding only. Plates are sealed with Topseal A and centrifuged 1 min, 800 rpm. Plates are loaded into a 1450 Microbeta TriLux (Perkin-Elmer) plate reader and the radioactivity counted after at least 4 hrs or overnight incubation at room temperature. Curve fitting and IC50 estimations are performed using a four parameter model in XLfit (IDBS, Guilford, UK) for Microdoft Excel (Microsoft, Redmond, Wash.).
- Scintillation Proximity Assay The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine or [3H]citalopram binding assays in recombinant human DAT, NET and SERT membranes with the SPA technology. The final assay volume is 50 μL in 384 well plates.Briefly, 0.5 μL of test compound in neat DMSO or 0.5 μL of DMSO for total binding (TB) or 0.5 μL of indatraline 1 mM (10 μM final concentration) for non specific binding (NSB) are added to the assay plate. 50 μL of the SPA mixture is added to each well, containing: 30 μg/mL or 10 μg/mL or 25 μg/mL DAT, NET, SERT membranes, respectively; 5 nM [3H]WIN-35,428 or 5 nM [3H]nisoxetine or 1 nM [3H]citalopram, for DAT, NET, SERT assay, respectively; 2.5 mg/mL or 1 mg/mL or 4 mg/mL WGA-PVT SPA beads (PerkinElmer RPNQ0001, for DAT, NET, SERT assay, respectively. All components are added to Assay Buffer (20 mM HEPES pH 7.4, 145 mM NaCl, 5 mM KCl, 0.01% Pluronic F-127). 0.02% BSA was used for DAT binding only. Plates are sealed with Topseal A and centrifuged 1 min, 800 rpm. Plates are loaded into a 1450 Microbeta TriLux (Perkin-Elmer) plate reader and the radioactivity counted after at least 4 hrs or overnight incubation at room temperature. Curve fitting and IC50 estimations are performed using a four parameter model in XLfit (IDBS, Guilford, UK) for Microdoft Excel (Microsoft, Redmond, Wash.).
- Sert Binding Assay Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 120 mmol/L NaCl and 5 mmol/L KCl) (the final concentration: about 2 nmol/L), 149 μL of h-SERT/CHO cell membrane sample (40 μg/well for the amount of protein), and 1 μL of a solution of a test compound in DMSO or a solvent (DMSO) was reacted at room temperature for 60 minutes, and then filtered promptly by aspiration under lower pressure with a glass fiber filter coated with a 0.05% aqueous polyethyleneimine solution. The filtered substance on the glass fiber filter was washed with 250 μL of SERT buffer twice, and then transferred to an ACS-II (Amersham) 4-mL-glass vial. The radioactivity of the filtered substance remained on the filter was measured by liquid scintillation counter. The radioactivity value measured by liquid scintillation counter was deemed to be a receptor binding activity, and the binding inhibition was calculated from the total binding (TB), non-specific binding (NSB), and specific binding (SB) of a test compound according to the following equations.
- Serotonin Transporter Binding Assay Brains from male Sprague-Dawley rats weighing 200-225 g (Taconic Labs, Germantown, N.Y.) were removed, midbrain dissected and rapidly frozen. Membranes were prepared by homogenizing tissues in 20 volumes (w/v) of 50 mM Tris containing 120 mM NaCl and 5 mM KCl, (pH 7.4 at 25° C.), using a Brinkman Polytron and centrifuged at 50,000xg for 10 min at 4° C. The resulting pellet was resuspended in buffer, recentrifuged and resuspended in buffer to a concentration of 15 mg/mL. Ligand binding experiments were conducted in assay tubes containing 0.5 mL buffer for 60 min at room temperature. Each tube contained 1.4 nM [3H]Citalopram (Amersham Biosciences, Piscataway, N.J.) and 1.5 mg midbrain tissue (original wet weight). Nonspecific binding was determined using 10 mM fluoxetine. Incubations were terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.3% polyethylenimine, using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, Md.). The filters were washed twice with 3 mL cold buffer and transferred to scintillation vials. Beckman Ready Value (3.0 mL) was added and the vials were counted the next day using a Beckman 6000 liquid scintillation counter (Beckman Coulter Instruments, Fullerton, Calif.).
- Binding Assay Receptor binding was performed using membrane fractions prepared from the HEK-293 cell line recombinantly expressing rat 5-HT7 receptors (NCBI accession NM_022938). Compound affinity for the rat 5-HT7 receptor subtype was evaluated by competitive radioligand binding assays using 5-carboxamido[3H]tryptamine ([3H]5-CT) (Amersham Biosciences, cat. 90000403) detection. HitHunter cAMP assays are in-vitro based competitive immunoassays. The assay was performed on the HEK-293 cell line stably transfected with r5-HT7 receptor. Cells were pre-incubated with test compounds for 10 minutes. For antagonist testing, the cells were then challenged with 100 nM 5-CT for 20 minutes. Cells were then lysed and cAMP measured according to manufacturers protocol (Amersham, cat. NET791250UC) or [3H]mesulergine (Amersham, cat. TRK1041). The assay was performed on membranes prepared from HEK-293 cells stably transfected with h5-HT6. Following centrifugation, membranes were resuspended and incubated for 60 min at room temperature with 1.7 nM [3H]LSD in the presence of increasing concentration of test compounds. Nonspecific binding was defined in the presence of 10 μM clozapine (Tocris, cat. TRK1068). Homogenized HEK-293 membranes expressing the human SERT were incubated in 50 mM Tris-HCl (pH 7.5), 120 mM NaCl, 5 mM KCl with [3H]-citalopram (3 nM) with or without test compounds. Nonspecific binding was determined in the presence of 10 μM fluoxetine. Radioactivity readouts and Ki values were performed as previously described for r5-HT7.
- Assay for Dopamine Reuptake Inhibition Uptake inhibition assay for the dopamine transporter was conducted in rat brain synaptosomes as described elsewhere with minor modifications (Rothman et al., Synapse 39, 32-41 (2001)). Freshly removed caudate was homogenized in 10% ice-cold sucrose with 12 strokes of a hand-held Potter-Elvehjem homogenizer followed by centrifugation at 1000×g for 10 min. The supernatants were saved on ice and used immediately. Transporter activity was assessed using 5 nM [3H]dopamine. The assay buffer was Krebs-phosphate buffer containing 154.4 mM NaCl, 2.9 mM KCl, 1.1 mM CaCl2, 0.83 mM MgCl2, 5 mM glucose, 1 mg/mL ascorbic acid, and 50 μM pargyline. The selectivity of the uptake assay for DAT was optimized by including 100 nM citalopram and 100 nM desipramine as blockers of SERT and NET in the sucrose solution and assay buffer. Uptake inhibition assays were conducted at 25° C. and were initiated by adding 100 μl of tissue to 900 μL assay buffer containing test drug and [3H]dopamine. Test drugs were diluted in assay buffer containing 1 mg/mL bovine serum albumin. Nonspecific uptake was measured by incubating in the presence of 10 μM indatraline. The reactions were stopped after 15 minutes by rapid vacuum filtration with a cell harvester (BRANDEL) over GF/B filters (Whatman) presoaked in wash buffer maintained at 25° C. (10 mM Tris-HCl, pH 7.4/150 mM NaCl). Filters were rinsed with 6 mL wash buffer and retained tritium was quantified by a MicroBeta liquid scintillation counter (PerkinElmer) after overnight extraction in 0.6 mL of liquid scintillation cocktail (Cytoscint, ICN). The data from three experiments were pooled and fit to a dose-response curve equation (using Kaleidagraph), to yield an Emax and EC50 value.